Quality of Life Study With Adalimumab in Rheumatoid Arthritis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Adalimumab; Methotrexate

Criteria

Inclusion Criteria:

• Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history

• Subject has a diagnosis of rheumatoid arthritis as defined by the 1987 ACR criteria

• Subjects with treatment failure criteria to Mtx or Mtx + another DMARD

Exclusion Criteria:

• Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

• Female subject who is pregnant or breast-feeding or considering becoming pregnant

• Previous treatment with approved biological agents (etanercept, infliximab, anakinra) in the last 2 months